Predicting disability outcomes in the modern era of multiple sclerosis treatment

Patients with relapsing–remitting multiple sclerosis (RRMS) treated with disease-modifying therapies (DMTs) in the modern era have a more favourable outlook than historical untreated cohorts. This was the conclusion from two recent publications describing disability outcomes and associated predictive factors in treated RRMS cohorts, using 10 years of ‘real-world’ follow-up data [1,2]. The main caveats to these analyses are the increasingly inclusive criteria for the diagnosis of MS that have been applied in recent years and the lack of published data in the historical cohorts on baseline clinico-radiological characteristics, which preclude any accurate comparisons. As with previous clinical, radiological and pathological studies,...